BRAF and melanoma: Treatment options for the second-line setting depend on the therapy used in the first line and include ipilimumab–nivolumab [II, B], pembrolizumab [I, A; ESMO-MCBS v1.1 score: A/4], nivolumab [II, B], ipilimumab [II, B; ESMO-MCBS v1.1 score: 4] and BRAFi–MEKi combination therapy for patients with BRAF-mutated melanoma [II, B; ESCAT score: I-A].